M
Massimo Offidani
Researcher at Marche Polytechnic University
Publications - 284
Citations - 14131
Massimo Offidani is an academic researcher from Marche Polytechnic University. The author has contributed to research in topics: Multiple myeloma & Lenalidomide. The author has an hindex of 50, co-authored 264 publications receiving 12094 citations. Previous affiliations of Massimo Offidani include Catholic University of the Sacred Heart & University of Bologna.
Papers
More filters
Journal ArticleDOI
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
Antonio Palumbo,Hervé Avet-Loiseau,Stefania Oliva,Henk M. Lokhorst,Hartmut Goldschmidt,Laura Rosiñol,Paul G. Richardson,S. Caltagirone,Juan J. Lahuerta,Thierry Facon,Sara Bringhen,Michel Attal,Roberto Passera,Andrew Spencer,Massimo Offidani,Shantanu Kumar,Pellegrino Musto,Sagar Lonial,Maria Teresa Petrucci,Robert Z. Orlowski,Elena Zamagni,Gareth J. Morgan,Maletios A. Dimopoulos,Brian G.M. Durie,Kenneth C. Anderson,Pieter Sonneveld,Jesús F. San Miguel,Michele Cavo,S. Vincent Rajkumar,Philippe Moreau +29 more
TL;DR: The R-ISS is a simple and powerful prognostic staging system, and it is recommended for use in future clinical studies to stratify patients with NDMM effectively with respect to the relative risk to their survival.
Journal ArticleDOI
The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study.
Livio Pagano,Morena Caira,Anna Candoni,Massimo Offidani,Luana Fianchi,Bruno Martino,Domenico Pastore,Marco Picardi,Alessandro Bonini,Anna Chierichini,Rosa Fanci,Cecilia Caramatti,Rosangela Invernizzi,Daniele Mattei,Maria Enza Mitra,Lorella Melillo,Franco Aversa,Maria Teresa Van Lint,Paolo Falcucci,Caterina Giovanna Valentini,Corrado Girmenia,Annamaria Nosari +21 more
TL;DR: Patients with hematologic malignancies are currently at higher risk of IFI caused by molds than by yeasts, and the incidence of I FI is highest among patients with acute myeloid leukemia.
Journal ArticleDOI
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study
Michele Cavo,Paola Tacchetti,Francesca Patriarca,Maria Teresa Petrucci,Lucia Pantani,Monica Galli,Francesco Di Raimondo,Claudia Crippa,Elena Zamagni,Antonio Palumbo,Massimo Offidani,Paolo Corradini,Franco Narni,Antonio Spadano,Norbert Pescosta,Giorgio Lambertenghi Deliliers,Antonio Ledda,Claudia Cellini,Tommaso Caravita,Patrizia Tosi,Michele Baccarani +20 more
TL;DR: VTD induction therapy before double autologous stem-cell transplantation significantly improves rate of complete or near complete response, and represents a new standard of care for patients with multiple myeloma who are eligible for transplant.
Journal ArticleDOI
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study
Meletios A. Dimopoulos,Philippe Moreau,Antonio Palumbo,Douglas E. Joshua,Ludek Pour,Roman Hájek,Thierry Facon,Heinz Ludwig,Albert Oriol,Hartmut Goldschmidt,Laura Rosiñol,Jan Straub,Aleksandr Suvorov,Carla Araujo,Elena Rimashevskaya,Tomas Pika,Gianluca Gaidano,Katja Weisel,Vesselina Goranova-Marinova,Anthony P. Schwarer,Leonard Minuk,Tamas Masszi,Ievgenii Karamanesht,Massimo Offidani,Vania Hungria,Andrew Spencer,Robert Z. Orlowski,Heidi H. Gillenwater,Nehal Mohamed,Shibao Feng,Wee Joo Chng +30 more
TL;DR: The primary endpoint was progression-free survival in the intention-to-treat population and carfilzomib with dexamethasone could be considered in patients with relapsed or refractory multiple myeloma.
Journal ArticleDOI
Autologous transplantation and maintenance therapy in multiple myeloma
Antonio Palumbo,Federica Cavallo,Francesco Di Raimondo,Dina Ben Yehuda,Maria Teresa Petrucci,Sara Pezzatti,Tommaso Caravita,Chiara Cerrato,Elena Ribakovsky,Mariella Genuardi,Anna Maria Cafro,Magda Marcatti,Lucio Catalano,Massimo Offidani,Angelo Michele Carella,Elena Zamagni,Francesca Patriarca,Pellegrino Musto,Andrea Evangelista,Giovannino Ciccone,Paola Omedè,Claudia Crippa,Paolo Corradini,Arnon Nagler,Mario Boccadoro,Michele Cavo +25 more
TL;DR: Consolidation therapy with high-dose melphalan plus stem-cell transplantation, as compared with MPR, significantly prolonged progression-free and overall survival among patients with multiple myeloma who were 65 years of age or younger.